Skip to main content

Dr Roberto Alonzi

Consultant Oncologist

BSc, MBBS, MRCP, FRCR, MD

Practises at: Bishops Wood Hospital, The Chiltern Hospital

Dr-Roberto-Alonzi-Orthopaedics

Personal Profile

Personal Profile

Dr Roberto Alonzi is a Medical Research Council Clinician Scientist with a special interest in Urological Malignancy. He has appointments as a Consultant Clinical Oncologist at Mount Vernon Cancer Centre and Bishops Wood Hospital and as a Senior Lecturer at University College London.

Dr Alonzi trained at Guy’s and St Thomas’ hospitals in London and achieved a 1st Class honours BSc degree followed by MBBS in 1997. Following his general training and membership of the Royal College of Physicians, his specialist training took place in London at Hammersmith hospital, Charing Cross hospital and Mount Vernon Cancer Centre resulting in a Fellowship of the Royal College of Radiologists in 2004.

Dr Alonzi studied for his research degree at the Gray Cancer Institute and University College London and was awarded an MD in 2008. He currently sits on the National Cancer Research Institute low-risk prostate cancer group and the bladder cancer chemo-radiotherapy group.

Dr Alonzi’s has a major academic interest in the treatment of prostate cancer. These research interests include the development of biologically targeted image-guided precision radiotherapy, tumour oxygenation, radiobiology and the use of radiation sensitizers in prostate cancer. He has also published work that characterises how the effects of hormone treatment alters the biology of prostate tumours.

Clinical Interests

Clinical Interests

  • Prostate cancer
  • Bladder cancer
  • Urological oncology
  • Brachytherapy
  • Radiotherapy
  • Chemotherapy
  • Immunotherapy
  • Gynaecological oncology
  • Cervix cancer
  • Uterine Cancer

Professional Memberships

Professional Memberships

  • The Royal College of Radiologists
  • The Royal College of Physicians
  • The European Society for Therapeutic Radiotherapy and Oncology
  • The American Association of Cancer Research
i